Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/emerald-publishing/a-critique-of-emerging-european-legislation-in-the-pharmaceutical-2skNTNP70K
References (11)
-
A. Earl‐Slater (1996)
Recent developments in regulating the pharmaceutical business in the EUEuropean Business Review, 96
-
EFPIA
The Pharmaceutical Industry in Figures -
EU
Clinical Trials Directive, European Parliament and of the Council -
R. McAdam, N. Barron (2002)
The role of quality management in pharmaceutical development: clinical trials analysisInternational Journal of Health Care Quality Assurance, 15
-
K. Kmietowicz
EU directive on clinical trials will cost lives -
A.D. Bhatt
Drug Studies: (Clinical) Trials and (Regulatory) Tribulations -
D. Bamford, P. Forrester (2003)
Managing planned and emergent change within an operations management environmentInternational Journal of Operations & Production Management, 23
-
S. Dorabjee, C. Lumley, S. Cartwright (1998)
Culture, innovation and successful development of new medicines ‐ an exploratory study of the pharmaceutical industryLeadership & Organization Development Journal, 19
-
A. Earl‐Slater (1997)
Recent legal and policy developments affecting the EU pharmaceutical business environmentEuropean Business Review, 97
-
Binshan Lin, J. Darling (1999)
An analysis of the formulation of strategic alliances: a focus on the pharmaceutical industryIndustrial Management and Data Systems, 99
-
A. Deighton, B. Mehentee
BARQA go wild at the zoo (the clinical trial directive guidelines)
- Publisher
- Emerald Publishing
- Copyright
- Copyright © 2004 Emerald Group Publishing Limited. All rights reserved.
- ISSN
- 0952-6862
- DOI
- 10.1108/09526860410563195
- Publisher site
- See Article on Publisher Site
Abstract
The objective of this paper is to critique emerging legislation in the pharmaceutical industry, focusing on the clinical trials sector. Possible changes are identified and discussed in relation to their impact on phase I clinical trials conducted in the UK. It is concluded that smaller contract research organisations, which have benefited in the past from European Union legislative variation, may have resource problems in trying to cope with the changing business environment created through legislative harmonization. These SMEs must use this opportunity to seek clinical trials research partnerships in a new harmonized EU market.
Journal
International Journal of Health Care Quality Assurance – Emerald Publishing
Published: Dec 1, 2004
Keywords: Pharmaceuticals industry; Clinical medicine; European Union information; Research organizations; Organizational change